Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases based on the University of California, San Francisco lab discoveries by co-founder Michael McGrath, today announced its corporate launch, the expansion of its executive team, and the creation of its Scientific Advisory Board. Neuvivo’s lead candidate, NP001, has received Orphan Drug and Fast Track designation by the FDA for use in ALS. The company’s near-term mission is to progress this candidate toward approval and deliver it to patients to reduce the suffering caused by this devastating disease.
